Skip to content

Study · Randomized controlled trial · n = 50 · 2017

1 result

Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

Braun LR, Feldpausch MN, Czerwonka N, Torriani M, Grinspoon SK, Stanley TL

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society7 Oct 2017Cited by 9 (Europe PMC)

PMID29031905 (opens in a new tab)PMCIDPMC5705434 (opens in a new tab)DOI10.1016/j.ghir.2017.10.002 (opens in a new tab)PepBankPUB-29031905
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialMechanism

    In HIV-infected adults with increased abdominal adiposity, serum FGF21 tended to decrease with tesamorelin versus placebo, but the difference was not significant.

    In plain wordsIn people with HIV and extra belly fat, a liver-related hormone, FGF21, tended to fall more with tesamorelin than with placebo, but not significantly.

    Peptide
    Tesamorelin
    Outcome
    No significant changeSerum FGF21 change
    Study

    n = 50

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    2 mg daily · six monthsAs given in this study (human).

    Source sentences

    Summary
    Log10 FGF21 tended to decrease in the tesamorelin group compared to placebo (p=0.06).
    1 context sentence
    Summary · context
    50 HIV-infected men and women with increased abdominal adiposity participated in this randomized, placebo-controlled trial of tesamorelin, 2mg vs. identical placebo daily for six months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT01263717

Effects of Growth Hormone Releasing Hormone in HIV

Massachusetts General Hospitaln = 54Dec 2010 to Feb 2014

HIV · HIV Lipodystrophy

Trial pageClinicalTrials.govUpdated 30 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.